Shilpa Medicare Ltd 2025 AR2

The report highlights Shilpa Medicare Limited's performance in the fiscal year 2024-25, showcasing a 13% revenue growth to ₹1,30,956 Lakhs and a 35% increase in EBITDA to ₹34,021 Lakhs. The company achieved significant milestones, including the out-licensing of Recombinant Human Albumin to Orion Corporation for European commercialization and receiving CDSCO approval for NorUDCA, India's first-in-class therapy for NAFLD. On the ESG front, the company transitioned to renewable energy, achieving 70% renewable energy consumption and reducing Scope 1 emissions by 22,000 tCO2e per annum through biomass utilization. Additionally, the company maintained its commitment to achieving net-zero greenhouse gas emissions by 2050.

Company: Shilpa Medicare Ltd

Sector: Health Care

Country: India

Year: 2025

Type: AR2

Pages: 298

Back to company

Shilpa Medicare Ltd

Shilpa Medicare Ltd 2025 Annual Report

Annual Report

The report highlights Shilpa Medicare Limited's performance in the fiscal year 2024-25, showcasing a 13% revenue growth to ₹1,30,956 Lakhs and a 35% increase in EBITDA to ₹34,021 Lakhs. The company achieved significant milestones, including the out-licensing of Recombinant Human Albumin to Orion Corporation for European commercialization and receiving CDSCO approval for NorUDCA, India's first-in-class therapy for NAFLD. On the ESG front, the company transitioned to renewable energy, achieving 70% renewable energy consumption and reducing Scope 1 emissions by 22,000 tCO2e per annum through biomass utilization. Additionally, the company maintained its commitment to achieving net-zero greenhouse gas emissions by 2050.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2025

Reporting Period

Apr 1, 2024 - Mar 31, 2025

Fiscal Year

2025

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Energy Consumption

Renewable Energy

Water Consumption

Total Waste

Women on Board

Women in Management

Workplace Fatalities

Net Zero Target

Employees